CorMedixNASDAQ: CRMD

The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.

CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Beth Zelnick Kaufman - Executive Vice President and Chief Legal Officer Liz Hulburt - Executive Vice President and Chief Clinical Strategy and Operations Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Jason Butler - Citizens JMP Gregory Renza - RBC Capital Brandon Folkes - Rodman & Renshaw Les Sulewski - Truist Securities Serge Belanger - Needham & Company Operator Good day and welcome to the CorMedix Inc. Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in the past, including management issues and regulatory delays, but now warrants a fresh look and valuation as the company executes on commercialization. DefenCath offers a unique solution for preventing catheter-related bloodstream infections, with the potential to reduce costs and save lives.

The 'Undercovered' Dozen highlights 12 lesser-covered stock ideas from October 18th - 24th, offering fresh investment takes for community discussion. Dnis Buivolov updates their Nebius Group valuation; core business Nebius AI targets a $260 billion market by 2030, driven by AI infrastructure demand. ASP Isotopes' breakthrough in Ytterbium-176 enrichment positions it as a key supplier in high-margin radiopharmaceutical and nuclear fuel markets according to Sean Daly.

BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.

Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

CorMedix (CRMD) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.25 per share a year ago.